GW2580CFMS kinase/CSF-1R inhibitor,selective and ATP-competitive CAS# 870483-87-7 |
2D Structure
- Balaglitazone
Catalog No.:BCC1395
CAS No.:199113-98-9
- Inolitazone
Catalog No.:BCC1652
CAS No.:223132-37-4
- Inolitazone dihydrochloride
Catalog No.:BCC1653
CAS No.:223132-38-5
- Aleglitazar
Catalog No.:BCC1337
CAS No.:475479-34-6
- L-165041
Catalog No.:BCC1687
CAS No.:79558-09-1
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 870483-87-7 | SDF | Download SDF |
PubChem ID | 11617559 | Appearance | Powder |
Formula | C20H22N4O3 | M.Wt | 366.41 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | GW-2580; CFMS Receptor Tyrosine Kinase Inhibitor;CSF-1 Receptor Inhibitor;GW 2580 | ||
Solubility | DMSO : 17.5 mg/mL (47.76 mM; Need ultrasonic and warming) | ||
Chemical Name | 5-[[3-methoxy-4-[(4-methoxyphenyl)methoxy]phenyl]methyl]pyrimidine-2,4-diamine | ||
SMILES | COC1=CC=C(C=C1)COC2=C(C=C(C=C2)CC3=CN=C(N=C3N)N)OC | ||
Standard InChIKey | MYQAUKPBNJWPIE-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C20H22N4O3/c1-25-16-6-3-13(4-7-16)12-27-17-8-5-14(10-18(17)26-2)9-15-11-23-20(22)24-19(15)21/h3-8,10-11H,9,12H2,1-2H3,(H4,21,22,23,24) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Potent and selective cFMS kinase inhibitor (IC50 = 0.06 μM). Exhibits selectivity for cFMS kinase over 186 other kinases. Inhibits CSF-1-induced growth of rat monocytes in vitro. Also inhibits bone resorption in osteoclast cultures, as well as connective tissue and bone destruction in a rat adjuvant arthritis model. Suppresses M-NFS-60 tumor cell growth in mice. Orally bioavailable. |
GW2580 Dilution Calculator
GW2580 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.7292 mL | 13.6459 mL | 27.2918 mL | 54.5837 mL | 68.2296 mL |
5 mM | 0.5458 mL | 2.7292 mL | 5.4584 mL | 10.9167 mL | 13.6459 mL |
10 mM | 0.2729 mL | 1.3646 mL | 2.7292 mL | 5.4584 mL | 6.823 mL |
50 mM | 0.0546 mL | 0.2729 mL | 0.5458 mL | 1.0917 mL | 1.3646 mL |
100 mM | 0.0273 mL | 0.1365 mL | 0.2729 mL | 0.5458 mL | 0.6823 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
GW2580 is a selective and orally bioavailable inhibitor of Colony-stimulating-factor-1 receptor (CSF-1R) with IC50 value of 30nM [1]
GW2580 has been demonstrated to be an extremely selective inhibitor for CSF-1R and has been hypothesized to bind to the DFG-out mode of CSF-1R, which might lock it into an inactive conformation [2] GW2580 has shown to inhibit epithelial cell-associated CSF-1 signaling, reduce Gr-1+ CD11b+ myeloid-derived suppressor cells (MDSCs) expansion, and alleviate the immune-suppressive microenvironment [3]. In addition, GW2580 suppressed IL-10 secretion in human glioblastoma cell line T98G [4].
References:
[1] Conway JG1, McDonald B, Parham J, Keith B, Rusnak DW, Shaw E, Jansen M, Lin P, Payne A, Crosby RM, Johnson JH, Frick L, Lin MH, Depee S, Tadepalli S,Votta B, James I, Fuller K, Chambers TJ, Kull FC, Chamberlain SD, Hutchins JT. Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580. Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):16078-83.
[2] Garcia AJ1, Ruscetti M, Arenzana TL, Tran LM, Bianci-Frias D, Sybert E, Priceman SJ, Wu L, Nelson PS, Smale ST, Wu H. Pten Null Prostate Epithelium Promotes Localized Myeloid-Derived Suppressor Cell Expansion and Immune Suppression during Tumor Initiation and Progression. Mol Cell Biol. 2014 Jun;34(11):2017-28.
[3] Kitagawa D1, Gouda M, Kirii Y, Sugiyama N, Ishihama Y, Fujii I, Narumi Y, Akita K, Yokota K. Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase. J Biochem. 2012 Jan;151(1):47-55.
[4] Komohara Y1, Horlad H, Ohnishi K, Fujiwara Y, Bai B, Nakagawa T, Suzu S, Nakamura H, Kuratsu J, Takeya M. Importance of direct macrophage-tumor cell interaction on progression of human glioma. Cancer Sci. 2012 Dec;103(12):2165-72.
- Bis-5,5-nortrachelogenin
Catalog No.:BCN6516
CAS No.:870480-56-1
- 3,23-Dioxo-9,19-cyclolanost-24-en-26-oic acid
Catalog No.:BCN1322
CAS No.:870456-88-5
- CAL-101 (Idelalisib, GS-1101)
Catalog No.:BCC1270
CAS No.:870281-82-6
- Acalisib (GS-9820)
Catalog No.:BCC6384
CAS No.:870281-34-8
- Apilimod mesylate
Catalog No.:BCC5287
CAS No.:870087-36-8
- Tozadenant
Catalog No.:BCC2011
CAS No.:870070-55-6
- A 839977
Catalog No.:BCC4290
CAS No.:870061-27-1
- xylitol pentacetate
Catalog No.:BCN6267
CAS No.:13437-68-8
- Inositol
Catalog No.:BCN8471
CAS No.:87-89-8
- D-Mannitol busulfan
Catalog No.:BCN3789
CAS No.:1187-00-4
- Tartaric acid
Catalog No.:BCN3824
CAS No.:87-69-4
- Pyrogallol
Catalog No.:BCN4424
CAS No.:87-66-1
- Ritanserin
Catalog No.:BCC7214
CAS No.:87051-43-2
- Zeylasteral
Catalog No.:BCN3065
CAS No.:87064-16-2
- Euphohelioscopin A
Catalog No.:BCN6501
CAS No.:87064-61-7
- PAP-1
Catalog No.:BCC1836
CAS No.:870653-45-5
- AC 261066
Catalog No.:BCC7848
CAS No.:870773-76-5
- Leptomycin B
Catalog No.:BCC7223
CAS No.:87081-35-4
- MK 0893
Catalog No.:BCC1752
CAS No.:870823-12-4
- E 2012
Catalog No.:BCC1540
CAS No.:870843-42-8
- Mulberrofuran G
Catalog No.:BCN3693
CAS No.:87085-00-5
- 5-Hydroxy-1,7-diphenyl-6-hepten-3-one
Catalog No.:BCN1321
CAS No.:87095-74-7
- Neuromedin B (porcine)
Catalog No.:BCC5841
CAS No.:87096-84-2
- 5-Methoxystrictamine
Catalog No.:BCN4416
CAS No.:870995-64-5
Effects of the cFMS kinase inhibitor 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine (GW2580) in normal and arthritic rats.[Pubmed:18434589]
J Pharmacol Exp Ther. 2008 Jul;326(1):41-50.
The cFMS (cellular homolog of the V-FMS oncogene product of the Susan McDonough strain of feline sarcoma virus) (Proc Natl Acad Sci U S A 83:3331-3335, 1986) kinase inhibitor 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine (GW2580) inhibits colony-stimulating factor (CSF)-1-induced monocyte growth and bone degradation in vitro and inhibits CSF-1 signaling through cFMS kinase in 4-day models in mice (Proc Natl Acad Sci U S A 102:16078, 2005). In the present study, the kinase selectivity of GW2580 was further characterized, and the effects of chronic treatment were evaluated in normal and arthritic rats. GW2580 selectively inhibited cFMS kinase compared with 186 other kinases in vitro and completely inhibited CSF-1-induced growth of rat monocytes, with an IC(50) value of 0.2 microM. GW2580 dosed orally at 25 and 75 mg/kg 1 and 5 h before the injection of lipopolysaccharide inhibited tumor necrosis factor-alpha production by 60 to 85%, indicating a duration of action of at least 5 h. In a 21-day adjuvant arthritis model, GW2580 dosed twice a day (b.i.d.) from days 0 to 21, 7 to 21, or 14 to 21 inhibited joint connective tissue and bone destruction as assessed by radiology, histology and bone mineral content measurements. In contrast, GW2580 did not affect ankle swelling in the adjuvant model nor did it affect ankle swelling in a model where local arthritis is reactivated by peptidoglycan polysaccharide polymers. GW2580 administered to normal rats for 21 days showed no effects on tissue histology and only modest changes in serum clinical chemistry and blood hematology. In conclusion, GW2580 was effective in preserving joint integrity in the adjuvant arthritis model while showing minimal effects in normal rats.
Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580.[Pubmed:16249345]
Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):16078-83.
Colony-stimulating-factor-1 (CSF-1) signaling through cFMS receptor kinase is increased in several diseases. To help investigate the role of cFMS kinase in disease, we identified GW2580, an orally bioavailable inhibitor of cFMS kinase. GW2580 completely inhibited human cFMS kinase in vitro at 0.06 microM and was inactive against 26 other kinases. GW2580 at 1 microM completely inhibited CSF-1-induced growth of mouse M-NFS-60 myeloid cells and human monocytes and completely inhibited bone degradation in cultures of human osteoclasts, rat calvaria, and rat fetal long bone. In contrast, GW2580 did not affect the growth of mouse NS0 lymphoblastoid cells, human endothelial cells, human fibroblasts, or five human tumor cell lines. GW2580 also did not affect lipopolysaccharide (LPS)-induced TNF, IL-6, and prostaglandin E2 production in freshly isolated human monocytes and mouse macrophages. After oral administration, GW2580 blocked the ability of exogenous CSF-1 to increase LPS-induced IL-6 production in mice, inhibited the growth of CSF-1-dependent M-NFS-60 tumor cells in the peritoneal cavity, and diminished the accumulation of macrophages in the peritoneal cavity after thioglycolate injection. Unexpectedly, GW2580 inhibited LPS-induced TNF production in mice, in contrast to effects on monocytes and macrophages in vitro. In conclusion, GW2580's selective inhibition of monocyte growth and bone degradation is consistent with cFMS kinase inhibition. The ability of GW2580 to chronically inhibit CSF-1 signaling through cFMS kinase in normal and tumor cells in vivo makes GW2580 a useful tool in assessing the role of cFMS kinase in normal and disease processes.